Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing, cancer screening, and other services in China. It offers general testing services comprising brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer's disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson's disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk assessment packages. The company also provides advanced testing services, which include hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; andRNF180/Septin9 gastric cancer screening test, as well as executive testing services, such as personal whole genome test and whole-exome sequencing package for adults. The company serves health checkup centers, hospitals, and various other customers. Mega Genomics Limited was founded in 2016 and is headquartered in Beijing, China.
Stock data | 2024 | Change |
---|---|---|
Price | $1.19 | N/A |
Market Cap | $282.70M | N/A |
Shares Outstanding | 237.77M | N/A |
Employees | 267.00 | N/A |